Fred Telling - 11 Dec 2025 Form 4/A - Amendment Insider Report for ORAGENICS INC (OGEN)

Reporting relationship: Director
Issuer ticker: OGEN
Reported as of: 11 Dec 2025
Net transaction value: -$198
SEC form: 4/A - Amendment
Accepted by SEC: 22 Jan 2026, 13:04:30 UTC
Original report date: 15 Dec 2025
Prior SEC filing: 09 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Fred Telling

Key filing fact

Fred Telling filed Form 4/A - Amendment for ORAGENICS INC (OGEN) on 22 Jan 2026.

Key facts

This page summarizes Fred Telling's Form 4/A - Amendment filing for ORAGENICS INC (OGEN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Jan 2026, 13:04.

Change

Previous filing in this sequence was filed on 09 Dec 2024.
Current net transaction value: -$198.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001382225 Primary reporting owner

Telling Fred

Relationship: Director
Address: 9015 TOWN CENTER PARKWAY, SUITE 143, LAKEWOOD RANCH
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Fred Telling
Signature date: 22 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OGEN transaction

Common Stock

Sale

Transaction value: $198
Shares: -210
Change %: -18%
Price: $0.9446
Shares after: 948
Date: 12 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OGEN transaction Derivative

Non-Employee Director Option (Right to Buy)

Award

Transaction value: $0
Shares: +125,000
Change %
Price: $0.000000
Shares after: 125,000
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $0.9300
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F2

This Amendment is being filed to correct the amount of securities beneficially owned. The Issuer effected a 1-for-30 reverse stock split of its outstanding common stock, which was not reflected on the prior Form 4.

Footnote F3

Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.